Clinical-stage Chinese biopharmaceutical company developing immuno-oncology and targeted cancer therapies.
Has no approved product and no sales; development is paid for by money raised from investors rather than by sales. Its fortunes ride on trial results for a handful of cancer drug candidates.
Products and services
Buparlisib (PI3K inhibitor, head/neck cancer)
AN4005 immuno-oncology candidate
Other early-stage oncology pipeline
Customers
Oncologists
Cancer patients (via approved therapy, pending)
Where it sits in the supply chain
Biotechnology
Oncology drug development
Immuno-oncology & targeted therapy…
What could go right
Buparlisib approval/launch potential
China oncology drug market growth
What could go wrong
Clinical trial failure risk
No approved/commercial product yet
Moat: none (IP / patents). Early clinical-stage pipeline with patent-protected candidates but no approved commercial product yet.
Headquarters: Hangzhou, China · Founded: 2016 · Employees: 109
SizeAdlai Nortye Ltd. Sponsored ADR (ANL) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $619M, the 2566th largest of 3,117 United States companies the cockpit tracks. Shares closed at $10.28 on 6 Nov 2026.
Performance Over six months the shares fell 22.6%, against +19.2% for the median peer and -1.1% for the United States market (cap-weighted) — 4th lowest of 9 in its peer set.
Growth The operating margin is -133.9% (peer median -10.0%).
Valuation It trades at 3.08× book value against a peer median of 1.86× (3rd most expensive of 9).
Price implies The share price implies a return on equity of about 31.2%; Adlai Nortye Ltd. Sponsored ADR delivers -20.3%, so the price asks more than the business earns today.
Short interest Short interest is 8.7% of the free float (15 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
Relative performance
Six months, rebased to 100: Adlai Nortye Ltd. Sponsored ADR against the median of its 8 peers (local-currency closes).
Adlai Nortye Ltd. Sponsored ADR financials
Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Performance: 6-month against 1-month return
Up and to the right = strong over both horizons. Adlai Nortye Ltd. Sponsored ADR is the large dot.
Fundamentals: return on equity against price-to-book
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Adlai Nortye Ltd. Sponsored ADR is the large dot.
Capital: ROE delivered against the ROE the price implies
Above the diagonal = the price asks for a higher return on equity than the business earns today. Adlai Nortye Ltd. Sponsored ADR is the large dot.
Adlai Nortye Ltd. Sponsored ADR competitors and peer comparison
Head to head with its named competitors (ANL vs 1801.HK vs 1877.HK vs 6887.HK)
How Adlai Nortye Ltd. Sponsored ADR compares with its peers
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
Adlai Nortye Ltd. Sponsored ADR against its 8 peers (data as of 6 Nov 2026)
Measure
ANL
Peer median
Rank in peer set
1-month return
-33.7%
+2.6%
lowest of 9
6-month return
-22.6%
+19.2%
4th lowest of 9
Return on equity
-20.3%
-29.9%
4th highest of 9
Price / book
3.08×
1.86×
3rd most expensive of 9
ROE the price implies
31.2%
14.8%
3rd most demanding of 9
ROE delivered
-20.3%
-29.9%
4th highest of 9
Peer table
Peer set: Industry: the same industry and sector in any market, nearest in size
Who are Adlai Nortye Ltd. Sponsored ADR's main competitors?
Named competitors: BeiGene (private or unlisted), Innovent Biologics (1801.HK), Junshi Biosciences (1877.HK), Zai Lab (6887.HK). The cockpit's measured peer set (industry) also includes Evotec (EVT.DE), OmniAb (OABI), SBC Medical (SBC), Evolent Health (EVH), Oculis (OCS), Tectonic Therapeutic (TECX).
Is Adlai Nortye Ltd. Sponsored ADR expensive compared with its peers?
On price / book it trades at 3.08× against a peer median of 1.86×, 3rd most expensive of 9 in its peer set. The share price implies a return on equity of about 31.2%; Adlai Nortye Ltd. Sponsored ADR delivers -20.3%, so the price asks more than the business earns today.
How has Adlai Nortye Ltd. Sponsored ADR stock performed?
Over six months to 6 Nov 2026 the shares returned -22.6% against +19.2% for the median peer; over one year +609.0%.